Micra transcatheter pacing system implantation via the right internal jugular vein: Preliminary results from a Polish multicenter registry.

BACKGROUND

Leadless pacemaker implantation via the right internal jugular vein (RIJV) is anemerging alternative to the traditional femoral approach, offering favorable anatomical access andpotential procedural advantages.

AIMS: Our aim was to assess the electrical performance, procedural efficiency and safety of Micraleadless pacemaker implantation via RIJV.

METHODS

Thirty-five consecutive patients who underwent Micra transcatheter pacing system (TPS) implantation via RIJV at 7 clinical centers in Poland between November 2024 and November2025 were included in this registry. The procedural safety and efficacy were assessed, and in-hospitalas well as short-term follow-up electrical parameters were analyzed.

RESULTS

Implantation success was achieved in 100% of cases. There were no significant changesin R-wave sensing (8.41 [2.45] vs. 9.20 [3.43] vs. 9.34 [3.60] mV; P = 0.45) or pacing threshold(0.5 [0.38-0.57] vs. 0.5 [0.38-0.63] vs. 0.5 [0.38-0.69] V; P = 0.25) between the procedure, predischarge,and 1-3-month follow-up. Impedance showed a significant decrease for a decrease across all timepoints (680 [620-745] vs. 630 [590-690] vs. 570 [535-607.5] Ω; P = 0.006). No mild or severe acuteor in-hospital complications related to the procedure were observed.

CONCLUSIONS

Micra TPS implantation via the RIJV is a highly effective and safe alternative to femoralaccess when performed in experienced cardiology centers.